[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 321,966,272
  • Shares Outstanding, K 2,469,824
  • Annual Sales, $ 65,011 M
  • Annual Income, $ 18,254 M
  • EBIT $ 12,969 M
  • EBITDA $ 18,807 M
  • 60-Month Beta 0.19
  • Price/Sales 5.01
  • Price/Cash Flow 11.54
  • Price/Book 7.09

Options Overview Details

View History
  • Implied Volatility 32.54% (-0.33%)
  • Historical Volatility 30.34%
  • IV Percentile 86%
  • IV Rank 79.05%
  • IV High 35.42% on 04/27/26
  • IV Low 21.66% on 12/08/25
  • Expected Move (DTE 1) 2.14 (1.68%)
  • Put/Call Vol Ratio 0.60
  • Today's Volume 3,202
  • Volume Avg (30-Day) 19,414
  • Put/Call OI Ratio 0.80
  • Today's Open Interest 440,547
  • Open Int (30-Day) 433,279
  • Expected Range 125.68 to 129.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.26
  • Number of Estimates 3
  • High Estimate $-0.21
  • Low Estimate $-0.36
  • Prior Year $2.13
  • Growth Rate Est. (year over year) -112.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
120.16 +6.61%
on 07/14/26
135.05 -5.15%
on 07/28/26
-0.40 (-0.31%)
since 06/30/26
3-Month
110.75 +15.67%
on 05/04/26
135.05 -5.15%
on 07/28/26
+18.92 (+17.33%)
since 04/30/26
52-Week
77.53 +65.23%
on 08/01/25
135.05 -5.15%
on 07/28/26
+46.35 (+56.70%)
since 07/30/25

Most Recent Stories

More News
Merck Announces Fourth-Quarter 2026 Dividend

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company’s common stock...

MRK : 128.42 (-1.49%)
Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development

Multi-faceted strategy aims to enable rapid, broad and sustainable access to alimatravir (MK-8527), if approved, in low- and middle-income countries Voluntary licensing...

MRK : 128.42 (-1.49%)
1 Dow Jones Stock with Exciting Potential and 2 Facing Headwinds

1 Dow Jones Stock with Exciting Potential and 2 Facing Headwinds

IBM : 221.48 (-2.19%)
JPM : 347.46 (+0.80%)
MRK : 128.42 (-1.49%)
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy

– High Rates of Virologic Suppression Sustained at Week 48 Across ISL/LEN Treatment Groups in Both Phase 3 ISLEND Trials – – ISL/LEN has the Potential...

MRK : 128.42 (-1.49%)
GILD : 129.25 (-2.62%)
Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure

– Long-Term Data from the PURPOSE 1 and PURPOSE 2 Trials Demonstrate Continued High Efficacy, High Adherence and Consistent Safety Profile of Twice-Yearly Lenacapavir for PrEP...

MRK : 128.42 (-1.49%)
GILD : 129.25 (-2.62%)
Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Merck (NYSE:MRK)

Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Merck (NYSE:MRK)

MRK : 128.42 (-1.49%)
Stocks Settle Lower as Chipmakers and AI Stocks Slump

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed down -0.51%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.20%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.62%. September...

MSTR : 95.96 (+2.82%)
GOOGL : 331.59 (-1.52%)
SNDK : 1,233.94 (+21.46%)
HL : 14.39 (+1.70%)
CDE : 14.95 (+2.19%)
GLXY : 20.71 (+13.42%)
FDXF : 139.40 (-3.44%)
COIN : 160.87 (+0.49%)
CRWV : 74.76 (+22.92%)
STX : 846.41 (+10.72%)
WDC : 531.58 (+15.05%)
AMD : 483.72 (+12.61%)
Stocks Mixed as Weakness in Chipmakers Weighs

The S&P 500 Index ($SPX ) (SPY ) today is down -0.14%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.21%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.96%. September E-mini S&P futures...

MSTR : 95.96 (+2.82%)
SNDK : 1,233.94 (+21.46%)
HL : 14.39 (+1.70%)
CDE : 14.95 (+2.19%)
GLXY : 20.71 (+13.42%)
FDXF : 139.40 (-3.44%)
COIN : 160.87 (+0.49%)
STX : 846.41 (+10.72%)
WDC : 531.58 (+15.05%)
AMD : 483.72 (+12.61%)
UPS : 103.03 (-1.46%)
SCCO : 181.42 (+3.39%)
Stocks Pressured by a Renewed Selloff in Chipmakers

The S&P 500 Index ($SPX ) (SPY ) today is down -0.46%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.28%. September E-mini S&P futures...

MSTR : 95.96 (+2.82%)
SAIA : 347.77 (-11.83%)
UAL : 121.97 (+2.14%)
AVGO : 383.34 (+3.52%)
SNDK : 1,233.94 (+21.46%)
GLXY : 20.71 (+13.42%)
MRK : 128.42 (-1.49%)
TXN : 279.90 (+3.17%)
FDXF : 139.40 (-3.44%)
$IUXX : 27,914.66 (+2.66%)
COIN : 160.87 (+0.49%)
ARCB : 139.69 (-1.27%)
Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia

At week 24 in the CORALreef Lipids and CORALreef HeFH trials, LIPFENDRA significantly reduced LDL-C by a placebo-adjusted 56% and 59%, respectively LIPFENDRA is a novel...

MRK : 128.42 (-1.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 135.19
2nd Resistance Point 133.94
1st Resistance Point 132.15
Last Price 128.42
1st Support Level 129.11
2nd Support Level 127.86
3rd Support Level 126.07

See More

52-Week High 135.05
Last Price 128.42
Fibonacci 61.8% 113.08
Fibonacci 50% 106.29
Fibonacci 38.2% 99.50
52-Week Low 77.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.